Document Dates

May 14, 2026 (Financial Statements) & September 09, 2026 (Corrigendum)

Key Details

Corrigendum Information

The company submitted a corrigendum to its Annual Report for FY 2025-26 dated September 03, 2026, to rectify inadvertent typographical errors identified in the Narrative and Director's Report sections. These corrections do not change the substance or meaning of the relevant disclosures. The revised report is available on BSE, NSE, and company websites (www.senorespharma.com).

Financial Performance Highlights

Consolidated Results:

  • Total Income: ₹679.69 Cr in FY25-26 (63% growth from ₹417.51 Cr in FY24-25)
  • Profit After Tax: ₹121.53 Cr in FY25-26 (108% growth from ₹58.34 Cr in FY24-25)
  • Earnings Per Share: ₹26.39 in FY25-26 (from ₹16.12 in FY24-25)
  • Cash Flow from Operations: ₹75 Cr

Standalone Results:

  • Revenue from Operations: ₹106.09 crore (FY26) vs ₹38.54 crore (FY25)
  • Profit Before Tax: ₹27.46 crore (FY26) vs ₹5.11 crore (FY25)
  • Profit After Tax: ₹20.25 crore (FY26) vs ₹3.69 crore (FY25)
  • Other Income: ₹66.35 crore, primarily from interest income (₹37.43 crore) and foreign exchange gains (₹28.11 crore)

Business Segment Performance

  • Regulated Markets: 68% of total revenue, primarily US market (70% of regulated markets revenue)
  • Emerging Markets: 23% of total revenue
  • Branded Generics: 385% growth in domestic business

Portfolio Expansion

  • ANDA Portfolio: Increased from 26 ANDAs (March 2025) to 51 ANDAs (March 2026) covering 150+ product strengths
  • Commercial Launches: 21 ANDAs commercially launched, 30 approved ANDAs (100+ strengths) planned for launch
  • Pipeline: 27 molecules (60+ strengths) under development

Strategic Acquisitions & Initiatives

  • Apnar Pharma: Acquired 75% stake for enterprise value of ₹91 Cr (remaining 25% expected by Q2 FY27). Includes USFDA-approved facility in Jambusar, Gujarat and 5 ANDAs (3 validated).
  • Zoraya Pharmaceuticals: Acquired 51% membership interest through Senores Pharmaceuticals Inc. Serves as US marketing and distribution platform.
  • Amerisyn Joint Venture: 70% JV for US government pharmaceutical supplies (addressable market of US$286 Mn from Veterans Affairs).
  • Havix Acquisition: Increased stake to 74.65% (57.69% direct + 16.96% through Senores Pharmaceuticals Inc)

Capital Structure & Financing

  • IPO Completion (FY25): Completed Initial Public Offer of 1,48,87,723 equity shares at ₹391 per share, raising ₹500 crore
  • IPO Proceeds Utilization: ₹394.98 crore utilized as of March 31, 2026 with ₹105.02 crore unutilized
  • Convertible Warrants: Allotted 11,70,000 convertible equity warrants on March 28, 2026 at ₹812 per warrant, raising ₹23.75 crore initially
  • Share Capital: Authorized ₹590,000,000; Paid-up ₹460,535,880

Investments and Subsidiary Support

  • Subsidiary Investments: Total ₹154.48 crore in subsidiaries including Senores Pharmaceuticals Inc (₹37.73 crore), Apnar Pharma (₹11.46 crore), Ratnatris Pharmaceuticals (₹28.42 crore), and Havix Group Inc (₹73.39 crore)
  • Loans to Subsidiaries: ₹360.98 crore provided for working capital purposes to various subsidiaries

Manufacturing Capacity

  • US Facility (Atlanta): Capacity increased from 1.2 billion units to 1.5 billion units
  • Sterile Manufacturing: Planned establishment of sterile manufacturing facility for injectables and biologics
  • API Capacity: Greenfield API facility at Chhatral targeted for USFDA approval with capacity expansion from 25 MTPA to 169 MTPA

Annual General Meeting

  • Date: September 25, 2026 at 11:30 AM IST
  • Mode: Video Conferencing/Other Audio-Visual Means
  • Agenda:
  • Adoption of audited standalone and consolidated financial statements
  • Re-appointment of directors retiring by rotation (Mr. Sanjay Majmudar and Mr. Arpit Shah)
  • Appointment of Mr. Viranchi Shah as Independent Director for 5 years
  • Approval of 'Senores Pharmaceuticals Employee Stock Option Scheme 2026' for 472,000 options
  • Approval for grant of ESOPs to subsidiary company employees

Regulatory Compliance & Auditing

  • Financial statements prepared in accordance with Indian Accounting Standards (Ind AS)
  • Audit conducted by Pankaj R Shah & Associates, Chartered Accountants
  • Unmodified audit opinion issued for both standalone and consolidated financial statements
  • Filed under Regulation 30 of SEBI Listing Regulations
  • Compliance with Companies Act, 2013 and SEBI Listing Obligations and Disclosure Requirements

Key Personnel

  • Managing Director: Mr. Swapnil Shah
  • Company Secretary & Compliance Officer: Ms. Shilpa Sharma (appointed w.e.f August 26, 2026)
  • CFO: Mr. Deval Shah

Market Information

  • Market Capitalization (as of March 31, 2026): ₹3,490.40 Cr
  • Listed on: BSE and NSE